BSE filing, NSE: ERIS. Summary written from the filing by ALFA Finder's alert engine.
Eris Lifesciences Ltd: key numbers
- Share price
- ₹1,160.20
- Market cap
- ₹16,096 Cr
- Revenue (annual)
- ₹3,129 Cr
- Net profit (annual)
- ₹619.5 Cr
- P/E (TTM)
- 22.8×Sector 45.9×
- Promoter holding
- 54.74%+0.60% QoQ
- FII holding
- 5.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Eris Lifesciences Ltd
All →Eris Lifesciences Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹892 Cr (+12.6%), PAT ₹187 Cr (+39.2%), EBITDA margin 34.7%. H1 PAT ₹330 Cr (+27.3%). Zorvia out-licensing supports DBF gross margin.
Eris Lifesciences Q2 FY27 Results: Net Profit ₹187.1 Cr, Up 39.1% YoY
Eris Lifesciences Ltd reported revenue from operations of ₹892.4 Cr (+12.6% YoY) and net profit of ₹187.1 Cr (+39.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹187.1 Cr · +39.1% YoY
Eris Lifesciences Board Meeting Date
Eris Lifesciences has scheduled a board meeting for October 26, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter ending September.
Eris Lifesciences Other Announcement
Eris Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Eris Lifesciences Debt & Borrowing: ₹1,250 Cr
Eris Lifesciences Limited submitted its half-yearly reporting of debt securities for the period ended September 30, 2026. Two tranches of NCDs totaling ₹1,250 Crore remain outstanding.
- Value
- ₹1,250 Cr
Eris Lifesciences Management Change
Eris Lifesciences Limited announced the resignation of Mr. Krishnakumar Vaidyanathan from his roles as Executive Director and Chief Operating Officer. The resignation was effective September 30, 2026.
Other adverse business impact announcements
All →Spandana Sphoorty Financial Adverse Business Impact
Cyber fraud debited ₹7.80 crore from Spandana Sphoorty's bank account on November 1, 2026. The company has reported to authorities and filed an insurance claim.
- Value
- ₹7.80 Cr
Medplus Health Services Adverse Business Impact
MedPlus Health Services' subsidiary Optival Health Solutions had its drug licence suspended for five days for a Suryapet store. Expected financial impact is about Rs 1.32 lakh.
- Value
- ₹0.01 Cr
- Execution
- 05 days
Oriental Rail Infrastructure Adverse Business Impact
Oriental Rail's subsidiary Oriental Foundry had a fire at its Kutch plant on 28 October 2026. Damage is minimal, operations are unaffected and the loss is insured.
Capillary Technologies India Adverse Business Impact
Capillary Technologies received KPMG's final forensic report on a cyber-enabled payment fraud at a step-down subsidiary. Four disputed payments totalled EUR 3.04 million, about Rs.32.24 Crore.
- Value
- ₹32.24 Cr
Windlas Biotech Adverse Business Impact
Windlas Biotech disclosed a cyber security incident on 30 October 2026. It states no material impact on core operations, finances or business continuity.
Neogen Chemicals Adverse Business Impact
Neogen Chemicals reports continued fire disruption at MPP3; replacement plant partly built with trial runs underway. Recognized damage totals ₹348.16 crore; production shifted to other sites.
- Value
- ₹348.2 Cr